M&A
confidence high
sentiment neutral
materiality 0.50
Immunome to acquire Atreca antibody assets for $5.5M upfront plus up to $7M milestones
Immunome Inc.
- Upfront cash payment of $5.5 million; additional $7.0 million in clinical development milestones.
- Assets include certain antibody-related assets and materials from Atreca, Inc.
- Transaction subject to customary conditions and Atreca stockholder approval.
- Immunome expects to expand its pipeline with the acquired assets.